Similar to CDK9 L156F, we found a nearly four-fold lower leukemic burden in mice injected with CDK7 L18F cells compared to those injected with WT B-ALL cells, reflecting a potential fitness defect in the CDK-mutant line (Figure 3f). This evidence concerns the gene CDK9 and acute lymphoblastic leukemia.